Patents by Inventor Robert G. Wisotzkey

Robert G. Wisotzkey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SLC19A2 amino acid transporter gene disruptions, and compositions and methods related thereto
    Patent number: 7176346
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in an SLC19A2 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: June 24, 2003
    Date of Patent: February 13, 2007
    Assignee: Deltagen, Inc.
    Inventor: Robert G. Wisotzkey
  • Mo54 gene disruptions, compositions and methods related thereto
    Publication number: 20030172390
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a Mo54 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: September 23, 2002
    Publication date: September 11, 2003
    Inventors: Robert G. Wisotzkey, Thadd C. Reeder
  • Carboxypeptidase N (CPN) disruptions, compositions and methods relating thereto
    Publication number: 20030167499
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a CPN gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: September 23, 2002
    Publication date: September 4, 2003
    Inventors: Robert G. Wisotzkey, Qin Zhang
  • CTSZ disruptions, compositions and methods relating thereto
    Publication number: 20030159168
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a CTSZ gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: September 23, 2002
    Publication date: August 21, 2003
    Inventors: Robert G. Wisotzkey, Christopher J. Kirk
  • Cathepsin G (CTSG) disruptions, compositions and methods relating thereto
    Publication number: 20030154503
    Abstract: The present invention relates to compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruption in a CTSG. The present invention also provides methods of identifying agents that modulate CTSG expression and function, useful models, and potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: September 23, 2002
    Publication date: August 14, 2003
    Inventors: Robert G. Wisotzkey, Christopher J. Kirk
  • GABA B1A receptor disruptions, compositions and methods relating thereto
    Publication number: 20030056238
    Abstract: The present invention relates to compositions and methods relating to the characterization, function, and uses of GABA-B1A. Specifically, the present invention provides transgenic animals comprising disruptions in GABA-B1A receptors. The present invention also provides methods of identifying agents that modulate GABA-B1A, useful models, and potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: June 24, 2002
    Publication date: March 20, 2003
    Inventor: Robert G. Wisotzkey